ABSTRACT
Introduction and Objectives: Colorectal cancer [CRC] has become a very common researched topic in Saudi Arabia. Significance of the disease lay as the third most common cancer in the Kingdom plus the various risk factors it may be connected to. Smoking, obesity, age, and gender should be further investigated in our community to focus our screening and minimize the burden of this disease. We tried to determine the differences between males and females in term of demographic, clinical and treatment characteristics
Methodology: A retrospective cohort study was performed in all cases of CRC from 2006-2014 in King Abdulaziz Medical City in Riyadh, Kingdom of Saudi Arabia [KSA]. Categorical data were presented as frequencies and percentages to summarize patients' demographic data. Chi-square was used to compare between sex and the site of metastasis. Moreover, Cox regression was used to assess the risk factors on mortality
Results: Out of 581 patients diagnosed with colorectal cancer, 326 [56.51%] were males. The mean age of colorectal patients at the time of diagnosis was 59.7. Majority of the BMI was overweight 183 [37.0%] smoking history was found in only 18 [3.5%] patients. Most of the patients were stage IV. The bio marker [K-RAS] was done for 189 colorectal cancer patients, of which male and female patients had mostly wild type. Tumor marker Carcinoembryonic Antigen [CEA] showed that most of the patients were in the high range for male patients 140[48.8%] and for females 115[53.2%]
Conclusion: No difference was found in regards to K-RAS mutation distribution by gender. High CEA was not associated to any age or gender. There was no statistical significance in relation to gender and response to treatment
ABSTRACT
Targeting epidermal growth factor receptor [EGFR] is an important treatment option for non-small cell lung cancer [NSCLC]. These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors harboring the EGFR mutations. In this manuscript, we will review in details the evolutions of these targeted therapy in the management of NSCLC.
ABSTRACT
Recognizing the significant prevalence of hepatocellular carcinoma [HCC] in Saudi Arabia, and the difficulties often faced in early and accurate diagnoses, evidence-based management, and the need for appropriate referral of HCC patients, the Saudi Association for the study of liver diseases and transplantation [SASLT] formed a multi-disciplinary task force to evaluate and update the previously published guidelines by the Saudi Gastroenterology Association. These guidelines were later reviewed, adopted and endorsed by the Saudi Oncology Society [SOS] as its official HCC guidelines as well. The committee assigned to revise the Saudi HCC guidelines was composed of hepatologists, oncologists, liver surgeons, transplant surgeons, and interventional radiologists. Two members of the task force served as guidelines editors. A wide based search on all published reports on all aspects of the epidemiology, natural history, risk factors, diagnosis, and management of HCC was performed. All available literature was critically examined and available evidence was then classified according to its strength. The whole document and the recommendations were then discussed in details by members and consensus was obtained. All recommendations in these guidelines were based on the best available evidence, but were tailored to the patients treated in Saudi Arabia. We hope that these guidelines will improve HCC patient care and enhance the multidisciplinary care needed for these patients